Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
absolute, accreted, accretion, accrual, adding, affiliated, anaplastic, appointsMICHAEL, apportioned, ArQule, auction, Australia, balloon, bone, brand, branded, cabozantinib, Canada, cap, closure, Codification, conceived, crizotinib, customary, debit, dispensed, Dr, Education, eleven, Eurodollar, exploratory, factory, follicular, foretinib, gap, Genitourinary, hepatocellular, hepatoma, imputed, inclined, incurrence, Insider, invasive, licensure, Lupe, MAb, mandatory, matter, mechanism, noncancelable, nondeductible, notional, Notwithstanding, Onyx, orphan, outlicensed, oversee, Overview, Pat, PDUFA, people, Poverty, PPACA, prepay, preserve, pressure, prioritization, priority, prostate, put, randomized, RDT, rebate, recommend, redundant, regained, resignation, resigned, retroactive, Rivera, Roche, ROR, settled, Silicon, slight, soft, stake, subtenant, systematic, twenty, unamortized, uncured, unfunded, unpaid, Valley, whichever, wrote
Removed:
accompany, acid, activate, activating, Agritope, AKT, amplification, analytical, apoptotic, assembled, assuring, atherosclerotic, attestation, basal, bile, bind, binding, bioavailable, biochemistry, blocked, blood, built, checkpoint, chemistry, chemo, cholesterol, circulating, clear, clinic, Cologne, combinatorial, commit, complementary, compounded, conference, congestive, create, cycle, cytoplasmic, damaging, deducting, defer, deregulation, DHh, diffuse, disposed, diverse, DNA, documented, downregulation, dyslipidemia, efficient, efficiently, elevated, elimination, Emerging, energy, enhance, eplerenone, ERK, erlotinib, excellent, exercising, facilitate, Farnesoid, fashion, fatty, finance, flexible, foam, formation, frequently, FXR, gastric, generation, genetic, Genomica, Germany, glioblastoma, guide, head, heart, hepatic, hereditary, hh, hypertension, identifying, IHh, industrial, inform, innovative, integration, iterative, kidney, LDL, learn, leverage, leveraging, ligand, lipid, lipoprotein, liver, lowered, LXRa, machinery, marked, maximizing, medicinal, medicine, medulloblastoma, mouse, multidisciplinary, myeloma, neck, nonclinical, nutrient, operational, optimized, orally, Oregon, organizational, pace, pancreatic, parent, permission, pharmacodynamic, pharmacology, phosphatase, phosphorylation, poorly, pressing, prime, prognostic, programming, prototype, published, qualify, ratio, recognizing, regulating, removed, renamed, renewed, repair, replication, rest, reverse, rodent, safe, secretion, segment, selecting, sensitivity, shelf, SHh, shorter, signal, smaller, smoothened, sooner, specifically, sporadic, stem, steroid, stimulation, streamlined, structural, sum, Symposia, syndrome, synergy, systemic, Task, transgenic, translated, translational, transmission, transport, treat, treating, triglyceride, underwriting, uniformly, validate, validated, vivo, wide, world, Wyeth
Filing tables
Filing exhibits
- 10-K Annual report
- 10.6 2000 Non-employee Directors' Stock Option Plan
- 10.7 Form of Stock Option Agreement
- 10.19 Offer Letter Agreement Between Exelixis, Inc. and Lupe M. Rivera
- 10.21 Compensation Information for the Company's Named Executive Officers
- 10.22 Compensation Information for Non-employee Directors
- 10.23 Exelixis, Inc. Change In Control and Severance Benefit Plan
- 10.39 Amendment No. 3, Dated October 8, 2010, to the Collaboration Agreement
- 10.46 Third Amendment to Lease Dated May 24, 2001
- 10.68 Amendment No. 3, Dated October 8, 2010, to the Collaboration Agreement
- 10.76 License Agreement, Dated October 8, 2010
- 10.77 Collaboration Agreement, Dated October 8, 2010
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification Required by Rule 13A-14(A) or Rule 15D-14(A)
- 31.2 Certification Required by Rule 13A-14(A) or Rule 15D-14(A)
- 32.1 Certification by the Chief Executive Officer and the Chief Financial Officer
Related press release
EXEL similar filings
Filing view
External links
Exhibit 10.21
COMPENSATION INFORMATION FOR NAMED EXECUTIVE OFFICERS
The table below provides information regarding the 2011 base salary and target cash bonus amount for each “named executive officer” of Exelixis, Inc.
2011 Annual | 2011 Target Cash Bonus | |||||||
Named Executive Officer | Base Salary | (% of 2011 Base Salary) | ||||||
Michael M. Morrissey (principal executive officer) | $ | 602,000 | 60 | % | ||||
Frank L. Karbe (principal financial officer) | $ | 426,368 | 45 | % | ||||
Frances K. Heller | $ | 424,350 | 45 | % | ||||
Gisela M. Schwab | $ | 418,399 | 45 | % |